Consider Our Overview Before Taking a Position in HZNP

Large-cap Healthcare company Horizon Therapeutics Public has logged a 0.7% change today on a trading volume of 193,732. The average volume for the stock is 2,971,438.

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Based in Dublin, Ireland the company has 2,095 full time employees and a market cap of $22,470,604,800.

The company is now trading -9.45% away from its average analyst target price of $109.5 per share. The 11 analysts following the stock have set target prices ranging from $76 to $140, and on average give Horizon Therapeutics Public a rating of buy.

Over the last year, HZNP shares have gone down by -3.5%, which represents a difference of 11.2% when compared to the S&P 500. The stock's 52 week high is $117.49 per share and its 52 week low is $57.84. Based on Horizon Therapeutics Public's average gross margin growth of 3.4% over the last four years, its core business remains strong and the stock price may recover in the long term.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.